<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00840944</url>
  </required_header>
  <id_info>
    <org_study_id>EUDRACT 2007-003247-70</org_study_id>
    <nct_id>NCT00840944</nct_id>
  </id_info>
  <brief_title>A 4 Year Combination Therapy of Growth Hormone and (GnRH) Agonist in Children With a Short Predicted Height</brief_title>
  <acronym>ZomaTrip</acronym>
  <official_title>Efficacy and Safety of a 4 Year Combination Therapy of Growth Hormone and Gonadotropin- Releasing Hormone Agonist in Children With a Short Predicted Height.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Belgian Study Group for Pediatric Endocrinology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Belgian Study Group for Pediatric Endocrinology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Estrogens are responsible for the disappearance of growth cartilage in the long bones at the
      end of the pubertal growth spurt both in boys and in girls. It is therefore hypothesized that
      stopping pubertal development and hence estrogen production, will prolong and increase the
      pubertal growth spurt, especially when growth hormone is given concommitantly.

      Boys in early puberty, with a bone age between 11 and 13 years and a predicted adult height
      below 163 cm or girls in early puberty with a bone age between 10 and 12 years and a
      predicted height under 151 cm will be treated with triptorelin 3.75 mg and Zomacton growth
      hormone for 4 years.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">April 2023</completion_date>
  <primary_completion_date type="Anticipated">January 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>height</measure>
    <time_frame>6 - 8 years</time_frame>
    <description>Difference between predicted height at start of treatment and adult height</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>bone density</measure>
    <time_frame>6 - 8 years</time_frame>
    <description>Bone density SDS measured by DEXA</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Idiopathic Short Stature</condition>
  <arm_group>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GnRH agonist triptorelin plus somatropin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>somatropin</intervention_name>
    <description>somatropin 0.050 mg/kg/day</description>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <other_name>growth hormone</other_name>
    <other_name>zomacton</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>triptorelin</intervention_name>
    <description>triptorelin 3.75 mg each month</description>
    <arm_group_label>ZOMATRIP</arm_group_label>
    <other_name>decapeptyl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult height prediction below -2.5 SD : 151 cm for girls and 164 cm for boys based on
             the vlaamse groeicurve 2004 (vub.ac.be/groeicurven)

          -  Pubertal: breast development at least M2 for girls and at least 4 ml of testicular
             volume for boys

          -  Bone age &gt;10 years but &lt; 12 years for girls and &gt; 11 but &lt; 13 years for boys

          -  Signed informed consent

        Exclusion Criteria:

          -  Adopted children ( different genetic background, lack of data on birth parameters and
             parents)

          -  Bone dysplasia or sitting height/ total height &gt; 2 SDS on standards by Gerver et al
             (see appendix)

          -  Chronic use of glucocorticoids

          -  Previous growth promoting therapy such as GH, sex steroids, oxandrolone,

          -  Known GH deficiency

          -  Chronic infectious disease

          -  Active rheumatic disease

          -  Previously diagnosed or currently suspected malignancy

          -  Sex steroid therapy

          -  Diabetes mellitus

          -  Renal insufficiency (serum creatinine &gt; 1.5 mg/dl)

          -  Hepatic disease ( liver test &gt; 4 fold upper limit of normality)

          -  Current congestive heart failure

          -  Inability to follow the study protocol

          -  Treatment with a non registered drug during the last 30 days before the moment of
             inclusion.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>7 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hilde Dotremont, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>BSGPE</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Antwerp University Hospital</name>
      <address>
        <city>Edegem</city>
        <state>Antwerpen</state>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jessah Ziekenhuis</name>
      <address>
        <city>Hasselt</city>
        <state>Limburg</state>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderziekenhuis UGent</name>
      <address>
        <city>Gent</city>
        <state>Oost Vlaanderen</state>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Universitaire Reine Fabiola (HUDERF)</name>
      <address>
        <city>Brussels</city>
        <zip>1050</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kinderziekenhuis UZ Brussel</name>
      <address>
        <city>Brussel</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU ND-des Bruy√®res</name>
      <address>
        <city>Liege</city>
        <zip>4030</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 10, 2009</study_first_submitted>
  <study_first_submitted_qc>February 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2009</study_first_posted>
  <last_update_submitted>November 29, 2017</last_update_submitted>
  <last_update_submitted_qc>November 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Belgian Study Group for Pediatric Endocrinology</investigator_affiliation>
    <investigator_full_name>Hilde Dotremont</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>gonadotropin releasing hormone agonist</keyword>
  <keyword>growth hormone</keyword>
  <keyword>final height</keyword>
  <keyword>bone density</keyword>
  <keyword>puberty</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dwarfism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Triptorelin Pamoate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

